Delivery Order SPE2DB22D2007-SPE2DB25FJ4CZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Contrave ER 8-90 mg tablets (120 count units) valued at $2,707.41. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,515.09 delivery order for Contrave ER 8-90 mg tablets (120-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,070.95 on July 29, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. As a delivery order, this award is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,391.13 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count unit). This is a firm fixed-price, non-set-aside contract with a completion date of July 29, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $6,406.51 to AmerisourceBergen Drug Corp for Contrave ER 8-90 mg tablets (120 count) on August 1, 2025, with completion targeted for August 4, 2025. This competitively awarded, firm fixed-price delivery order utilizes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $22,397.23 to AmerisourceBergen Drug Corp for Contrave ER 8-90 mg tablets (120 count) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,792.54 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120-count units) under a firm fixed-price contract. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,358.10 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120-count units). The contract, awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the vendor's facility in Conshohocken, Pennsylvania. This award is issued as a child order under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Contrave ER 8-90 mg tablets (120-count packages). The contract, valued at $2,533.30, represents a firm fixed-price delivery order with no set-aside designation and an ultimate completion date of August 19, 2025. This award is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $4,065.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Contrave ER 8-90 mg tablets (120-count units) on August 13, 2025, with completion targeted for August 14, 2025. This non-set-aside award represents a standard pharmaceutical supply transaction under the company's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4CZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,713.86 to AmerisourceBergen Drug Corp for the supply of Contrave ER 8-90 mg tablets (120-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will occur at the vendor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that authorizes the company to supply comprehensive pharmaceutical products and medical supplies to support military and federal healthcare systems globally. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly for the Defense Health Agency and military healthcare networks. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive procurements across diverse therapeutic areas, from specialty medications to vaccines and medical devices. This specific delivery order for Contrave, an FDA-approved weight management medication, aligns with the company's established role as a primary vendor for pharmaceutical commodities supporting defense and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/19/25 |